Cancer Chemotherapy and Pharmacology

, Volume 72, Issue 1, pp 127–138 | Cite as

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues

  • Krupa J. Patel
  • Olivier Trédan
  • Ian F. Tannock
Original Article
First Online:
Received:
Accepted:

Abstract

Purpose

Pharmacokinetic analyses estimate the mean concentration of drug within a given tissue as a function of time, but do not give information about the spatial distribution of drugs within that tissue. Here, we compare the time-dependent spatial distribution of three anticancer drugs within tumors, heart, kidney, liver and brain.

Methods

Mice bearing various xenografts were treated with doxorubicin, mitoxantrone or topotecan. At various times after injection, tumors and samples of heart, kidney, liver and brain were excised.

Results

Within solid tumors, the distribution of doxorubicin, mitoxantrone and topotecan was limited to perivascular regions at 10 min after administration and the distance from blood vessels at which drug intensity fell to half was ~25–75 μm. Although drug distribution improved after 3 and 24 h, there remained a significant decrease in drug fluorescence with increasing distance from tumor blood vessels. Drug distribution was relatively uniform in the heart, kidney and liver with substantially greater perivascular drug uptake than in tumors. There was significantly higher total drug fluorescence in the liver than in tumors after 10 min, 3 and 24 h. Little to no drug fluorescence was observed in the brain.

Conclusions

There are marked differences in the spatial distributions of three anticancer drugs within tumor tissue and normal tissues over time, with greater exposure to most normal tissues and limited drug distribution to many cells in tumors. Studies of the spatial distribution of drugs are required to complement pharmacokinetic data in order to better understand and predict drug effects and toxicities.

Keywords

Drug distribution Tumor microenvironment Normal tissues Doxorubicin Mitoxantrone Topotecan 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We would like to acknowledge the Pathology Research Program at Toronto General Hospital for providing support with immunohistochemical staining. This work was supported by a Grant from the Canadian Institute for Health Research.

Conflict of interest

None.

References

  1. 1.
    Adamson PC, Zimm S, Ragab AH, Steinberg SM, Balis F, Kamen BA, Vietti TJ, Gillespie A, Poplack DG (1990) A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 26:343–344PubMedCrossRefGoogle Scholar
  2. 2.
    Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3:101–107PubMedGoogle Scholar
  3. 3.
    Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL (1985) Disposition of mitoxantrone in cancer patients. Cancer Res 45:1879–1884PubMedGoogle Scholar
  4. 4.
    Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159–165PubMedCrossRefGoogle Scholar
  5. 5.
    Benjamin RS, Riggs CE Jr, Bachur NR (1977) Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37:1416–1420PubMedGoogle Scholar
  6. 6.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257PubMedCrossRefGoogle Scholar
  7. 7.
    Crawford AR, Lin XZ, Crawford JM (1998) The normal adult human liver biopsy: a quantitative reference standard. Hepatology 28:323–331PubMedCrossRefGoogle Scholar
  8. 8.
    De Cesare M, Zunino F, Pace S, Pisano C, Pratesi G (2000) Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts. Eur J Cancer 36:1558–1564PubMedCrossRefGoogle Scholar
  9. 9.
    de Vries NA, Ouwehand M, Buckle T, Beijnen JH, van Tellingen O (2007) Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomed Chromatogr 21:1191–1200PubMedCrossRefGoogle Scholar
  10. 10.
    Devalapally H, Rajan KS, Akkinepally RR, Devarakonda RK (2008) Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. Drug Dev Ind Pharm 34:789–795PubMedCrossRefGoogle Scholar
  11. 11.
    Dorr RT (1996) Cytoprotective agents for anthracyclines. Semin Oncol 23:23–34PubMedGoogle Scholar
  12. 12.
    Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41:400–449PubMedCrossRefGoogle Scholar
  13. 13.
    Fujita H, Okamoto M, Takao A, Abe H, Ishii R, Takeda K (1995) Pharmacokinetics of SK and F 104864 in experimental animals. I. Plasma level. Gan To Kagaku Ryoho 22:1783–1787PubMedGoogle Scholar
  14. 14.
    Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727–741PubMedCrossRefGoogle Scholar
  15. 15.
    Gonzalez-Paz O, Polizzi D, De Cesare M, Zunino F, Bigioni M, Maggi CA, Manzini S, Pratesi G (2001) Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice. Eur J Cancer 37:431–437PubMedCrossRefGoogle Scholar
  16. 16.
    Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312–3322PubMedGoogle Scholar
  17. 17.
    Grantab R, Sivananthan S, Tannock IF (2006) The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 66:1033–1039PubMedCrossRefGoogle Scholar
  18. 18.
    Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 43:3417–3421PubMedGoogle Scholar
  19. 19.
    Gustafson DL, Rastatter JC, Colombo T, Long ME (2002) Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 91:1488–1501PubMedCrossRefGoogle Scholar
  20. 20.
    Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O’Dwyer PJ (1994) Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 54:1220–1226PubMedGoogle Scholar
  21. 21.
    Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363–1380PubMedCrossRefGoogle Scholar
  22. 22.
    Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54(Suppl 4):1–7PubMedCrossRefGoogle Scholar
  23. 23.
    Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878PubMedGoogle Scholar
  24. 24.
    Jain KK (2000) Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Investig Drugs 9:1139–1149PubMedCrossRefGoogle Scholar
  25. 25.
    Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48:2641–2658PubMedGoogle Scholar
  26. 26.
    Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271:58–65PubMedCrossRefGoogle Scholar
  27. 27.
    Jain RK (1996) Delivery of molecular medicine to solid tumors. Science 271:1079–1080PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson JL, Ahmad A, Khan S, Wang YF, Abu-Qare AW, Ayoub JE, Zhang A, Ahmad I (2004) Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation. J Chromatogr B Analyt Technol Biomed Life Sci 799:149–155PubMedCrossRefGoogle Scholar
  29. 29.
    Lankelma J, Dekker H, Luque FR, Luykx S, Hoekman K, van der Valk P, van Diest PJ, Pinedo HM (1999) Doxorubicin gradients in human breast cancer. Clin Cancer Res 5:1703–1707PubMedGoogle Scholar
  30. 30.
    Less JR, Skalak TC, Sevick EM, Jain RK (1991) Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51:265–273PubMedGoogle Scholar
  31. 31.
    Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351–375PubMedCrossRefGoogle Scholar
  32. 32.
    Milosevic MF, Fyles AW, Wong R, Pintilie M, Kavanagh MC, Levin W, Manchul LA, Keane TJ, Hill RP (1998) Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 82:2418–2426PubMedCrossRefGoogle Scholar
  33. 33.
    Nederman T, Carlsson J (1984) Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 13:131–135PubMedCrossRefGoogle Scholar
  34. 34.
    Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF (2005) The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11:8782–8788PubMedCrossRefGoogle Scholar
  35. 35.
    Rentsch KM, Horber DH, Schwendener RA, Wunderli-Allenspach H, Hanseler E (1997) Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Br J Cancer 75:986–992PubMedCrossRefGoogle Scholar
  36. 36.
    Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH et al (1992) Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10:647–656PubMedGoogle Scholar
  37. 37.
    Sartiano GP, Lynch WE, Bullington WD (1979) Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential inhibition of DNA polymerase alpha. J Antibiot (Tokyo) 32:1038–1045CrossRefGoogle Scholar
  38. 38.
    Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105:67–81PubMedCrossRefGoogle Scholar
  39. 39.
    Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8:878–884PubMedGoogle Scholar
  40. 40.
    Tosoni A, Ermani M, Brandes AA (2004) The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev Oncol Hematol 52:199–215PubMedCrossRefGoogle Scholar
  41. 41.
    Tredan O, Garbens AB, Lalani AS, Tannock IF (2009) The hypoxia-activated ProDrug AQ4 N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res 69:940–947PubMedCrossRefGoogle Scholar
  42. 42.
    Tunggal JK, Cowan DS, Shaikh H, Tannock IF (1999) Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 5:1583–1586PubMedGoogle Scholar
  43. 43.
    Urva SR, Shin BS, Yang VC, Balthasar JP (2009) Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 877:837–841PubMedCrossRefGoogle Scholar
  44. 44.
    von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667Google Scholar
  45. 45.
    Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19:670–686PubMedGoogle Scholar
  46. 46.
    Wilkinson PM, Israel M, Pegg WJ, Frei E 3rd (1979) Comparative metabolism and excretion of adriamycin in man, monkey, and rat. Cancer Chemother Pharmacol 2:121–125PubMedCrossRefGoogle Scholar
  47. 47.
    Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305:139–153PubMedCrossRefGoogle Scholar
  48. 48.
    Zheng JH, Chen CT, Au JL, Wientjes MG (2001) Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci 3:E15PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Krupa J. Patel
    • 1
  • Olivier Trédan
    • 2
  • Ian F. Tannock
    • 1
    • 3
  1. 1.Department of Medical BiophysicsPrincess Margaret Cancer Centre and University of TorontoTorontoCanada
  2. 2.Départementd’Oncologie MédicaleCentre Léon BérardLyonFrance
  3. 3.Division of Medical Oncology and HematologyPrincess Margaret Cancer Centre and University of TorontoTorontoCanada

Personalised recommendations